Effect of nucleotide binding oligomerization domain-like receptor protein 3 inflammasome on in-stent restenosis after coronary stent implantation
-
摘要:目的 探讨核苷酸结合寡聚化结构域样受体蛋白3（NLRP3）炎症小体的表达水平与冠状动脉支架植入术后支架内再狭窄（ISR）的相关关系。方法 选取住院治疗并成功行初次经皮冠状动脉介入治疗（PCI）术的患者150例，术前、术后24 h应用免疫印迹法定量分析NLRP3。1年后复查冠状动脉造影，根据ISR诊断标准将患者分为ISR组（n=22）与对照组（n=128），分析NLRP3表达水平与ISR严重程度的相关关系。结果 1年后复查时，ISR组NLRP3表达水平较对照组升高，差异有统计学意义（P < 0.05），且在一定范围内随着ISR严重程度的升高，NLRP3表达水平可逐渐增高，二者存在简单线性正相关关系（r=0.862，P=0.001）。结论 NLRP3表达水平与冠状动脉ISR严重程度呈正相关。
-
关键词:
- 核苷酸结合寡聚化结构域样受体蛋白3 /
- 炎症 /
- 冠状动脉 /
- 支架内再狭窄
Abstract:Objective To investigate the relationship between the expression of inflammatory bodies nucleotide binding oligomerization domain-like receptor protein 3 (NLRP3) and in-stent restenosis(ISR) after coronary stent implantation.Methods A total of 150 hospitalized patients who successfully underwent primary percutaneous coronary intervention (PCI) were selected. NLRP3 was quantitatively analyzed by Western Blot before and 24 hours after PCI. Coronary angiography was reexamined one year later. According to ISR diagnostic criteria, they were divided into ISR group (n=22) and control group (n=128), and the correlation between the expression level of NLRP3 and the severity of ISR was analyzed.Results One year later, the expression level of NLRP3 in the ISR group was significantly higher than that in the control group (P < 0.05), and the NLRP3 expression level was gradually increased with the increase of ISR severity within a certain range. They showed a simple linear positive correlation between NLRP3 and ISR severity (r=0.862, P=0.001).Conclusion The expression level of NLRP3 is positively related to the severity of coronary ISR. -
-
表 1 2组患者治疗前基线资料比较(x±s)[n(%)]
基线资料 ISR组(n=22) 对照组(n=128) P 病程/年 2.96±2.93 2.51±2.24 0.406 男性 11(50.0) 77(60.2) 0.372 年龄/岁 67.55±12.23 67.09±13.57 0.882 收缩压/mmHg 123.77±18.64 123.66±17.45 0.979 心率/(次/min) 93.27±20.21 89.09±18.92 0.344 总胆固醇/(mmol/L) 3.57±0.82 3.87±1.03 0.189 低密度脂蛋白胆固醇/(mmol/L) 2.14±0.19 2.31±0.68 0.236 既往病史 心肌病 4(18.2) 36(28.1) 0.330 高血压 15(68.2) 68(53.1) 0.189 房颤 1(4.5) 15(11.7) 0.314 冠心病 14(63.6) 70(54.7) 0.435 糖尿病 4(18.2) 36(28.1) 0.330 吸烟 4(18.2) 22(17.2) 0.909 用药情况 硝酸酯类药物 7(31.8) 40(31.3) 0.958 β受体阻滞剂 9(40.9) 64(50.0) 0.431 洋地黄 2(9.1) 12(9.4) 0.966 抗血小板类药物 14(63.6) 72(56.3) 0.518 他汀类药物 12(54.5) 72(56.3) 0.882 利尿剂 8(36.4) 52(40.6) 0.706 
下载: 导出CSV
表 2 2组患者NLRP3表达水平比较(x±s)
pg/mL 组别 PCI术前 PCI术后24 h 1年后复查时 ISR组(n=22) 353.91±44.50 397.82±66.59* 425.36±64.84**# 对照组(n=128) 335.04±65.86 376.31±50.88** 342.55±65.68 NLRP3: 核苷酸结合寡聚化结构域样受体蛋白3; ISR: 支架内再狭窄。
与PCI术前比较, * P < 0.05, * * P < 0.01; 与对照组比较, #P < 0.05。
下载: 导出CSV
表 3 各组患者1年后复查时NLRP3水平比较(x±s)
pg/mL 组别 n NLRP3 对照组 128 342.55±65.68 轻度狭窄组 9 367.00±81.45 中度狭窄组 7 399.43±67.81 重度狭窄组 4 438.25±57.41 极重狭窄组 2 501.50±31.82 F 5.87 P 0.01 NLRP3: 核苷酸结合寡聚化结构域样受体蛋白3;
ISR: 支架内再狭窄。
下载: 导出CSV
-
[1] EISEN A, GIUGLIANO R P, BRAUNWALD E. Updates on acute coronary syndrome: a review[J]. JAMA Cardiol, 2016, 1(6): 718-730. doi: 10.1001/jamacardio.2016.2049
[2] 林欣, 杨滨, 王晔玲. 冠脉支架植入术后炎症反应对再狭窄影响的研究进展[J]. 中国老年学杂志, 2019, 39(1): 233-236. doi: 10.3969/j.issn.1005-9202.2019.01.079 [3] 张宇, 徐立, 李涵, 等. 视黄醇结合蛋白4与冠心病患者冠脉病变程度的相关性研究[J]. 标记免疫分析与临床, 2015, 22(10): 964-967. https://www.cnki.com.cn/Article/CJFDTOTAL-BJMY201510006.htm [4] 董元宝, 尹丽娟, 李伟真, 等. 外周血单核细胞表达Nod样受体蛋白炎症小体与冠状动脉病变程度的相关性[J]. 中国慢性病预防与控制, 2015, 23(5): 347-349. https://www.cnki.com.cn/Article/CJFDTOTAL-ZMXB201505008.htm [5] WANG X M, LI X W, WU Y H, et al. Upregulation of miR-223 abrogates NLRP3 inflammasome-mediated pyroptosis to attenuate oxidized low-density lipoprotein (ox-LDL)-induced cell death in human vascular endothelial cells (ECs)[J]. Vitro Cell Dev Biol Animal, 2020, 56(8): 670-679. doi: 10.1007/s11626-020-00496-9
[6] 胡龙江, 周音频, 曹运兰, 等. NLRP3炎性小体与冠心病的相关性[J]. 中国动脉硬化杂志, 2018, 26(3): 281-286. doi: 10.3969/j.issn.1007-3949.2018.03.012 [7] KELLEY N, JELTEMA D, DUAN Y H, et al. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation[J]. Int J Mol Sci, 2019, 20(13): 3328. doi: 10.3390/ijms20133328
[8] USUI F, SHIRASUNA K, KIMURA H, et al. Critical role of caspase-1 in vascular inflammation and development of atherosclerosis in Western diet-fed apolipoprotein E-deficient mice[J]. Biochem Biophys Res Commun, 2012, 425(2): 162-168. doi: 10.1016/j.bbrc.2012.07.058
[9] BLANKENBERG S, TIRET L, BICKEL C, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina[J]. Circulation, 2002, 106(1): 24-30. doi: 10.1161/01.CIR.0000020546.30940.92
[10] GREBE A, HOSS F, LATZ E. NLRP3 inflammasome and the IL-1 pathway in atherosclerosis[J]. Circ Res, 2018, 122(12): 1722-1740. doi: 10.1161/CIRCRESAHA.118.311362
[11] 万招飞, 刘小军, 薛嘉虹, 等. NLRP3炎症小体在糖尿病患者动脉粥样硬化的作用[J]. 山西医科大学学报, 2019, 50(10): 1399-1402. https://www.cnki.com.cn/Article/CJFDTOTAL-SXYX201910013.htm [12] LIU S, LIAO Q, XU W, et al. MiR-129-5p protects H9c2 cardiac myoblasts from hypoxia/reoxygenation injury by targeting TRPM7 and inhibiting NLRP3 inflammasome activation[J]. J Cardiovasc Pharmacol, 2021, 77(5): 586-593. http://www.ncbi.nlm.nih.gov/pubmed/33951695
[13] SATISH M, AGRAWAL D K. Atherothrombosis and the NLRP3 inflammasome-endogenous mechanisms of inhibition[J]. Transl Res, 2020, 215: 75-85. doi: 10.1016/j.trsl.2019.08.003
[14] XIA J, ZHANG J, CHANG J, et al. The effects of glycaemic variability on intimal hyperplasia and plaque stability after stenting via autophagy-mediated G3BP1/NLRP3 inflammasome[J]. Ann Transl Med, 2020, 8(21): 1388. doi: 10.21037/atm-20-4818
[15] SILVIS M J M, DEMKES E J, FIOLET A T L, et al. Immunomodulation of the NLRP3 inflammasome in atherosclerosis, coronary artery disease, and acute myocardial infarction[J]. J Cardiovasc Transl Res, 2021, 14(1): 23-34. doi: 10.1007/s12265-020-10049-w
-
期刊类型引用(2)
1. 欧冬冬. 乙酰半胱氨酸雾化联合罗红霉素分散片对重症支原体肺炎患儿的影响. 中外医学研究. 2025(05): 123-126 . 
百度学术
2. 姜秀明，李建卫. 乙酰半胱氨酸雾化吸入联合盐酸莫西沙星氯化钠注射治疗老年重症肺炎的效果观察. 中国药物滥用防治杂志. 2024(12): 2284-2285+2288 . 百度学术
其他类型引用(0)
计量
- 文章访问数: 359
- HTML全文浏览量: 219
- PDF下载量: 21
- 被引次数: 2
苏公网安备 32100302010246号
